A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects With Hepatocellular Carcinoma

Trial Profile

A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects With Hepatocellular Carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Foretinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Nov 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 21 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 02 Dec 2014 Planned End Date changed from 1 May 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top